SCHEMBL2197162

SCHEMBL2197162

Nc1cccc2cc(Br)cnc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
HTT P42858 2/20 0.41
DYRK1A Q13627 1/20 0.41
EGFR P00533 1/20 0.38
KDM4E B2RXH2 5/20 0.37
PSMD14 O00487 2/20 0.37
COPS5 Q92905 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
LMNA P02545 2/20 0.36
CYP3A4 P08684 2/20 0.36
BACE1 P56817 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
PARP1 P09874 1/20 0.36
PDPK1 O15530 1/20 0.35
POLB P06746 2/20 0.35
RAB9A P51151 2/20 0.35
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14661368 0.77 KDM4E (0.44) HTTKDM4EPSMD14COPS5TDP1
SCHEMBL14923574 0.77 KDM4E (0.38) KMT2AKDM4EPSMD14COPS5LMNA
SCHEMBL3385960 0.77 KDM4E (0.62) KMT2AKDM4ELMNAALDH1A1MEN1
SCHEMBL5558125 0.77 NR4A2 (0.38) KDM4EPSMD14COPS5LMNACYP1A2
SCHEMBL10321093 0.77 BACE1 (0.39) KMT2AKDM4EPSMD14COPS5TDP1
SCHEMBL3708915 0.77 KDM4E (0.37) KMT2AKDM4EPSMD14COPS5TDP1
SCHEMBL31588980 0.77 KDM4E (0.37) KMT2AKDM4EPSMD14COPS5TDP1
SCHEMBL8489038 0.77 KDM4E (0.44) KDM4EPSMD14COPS5TDP1PARP1
SCHEMBL29800848 0.77 KDM4E (0.62) KDM4EPSMD14COPS5TDP1CYP1A2
SCHEMBL11973584 0.77 KDM4E (0.62) KDM4EPSMD14COPS5TDP1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113072585-B Preparation of chiral aryl phosphonic acid cyclic diester and derivative thereof 厦门市博瑞来医药科技有限公司 2023-11-10 CN claimed
CN-110270295-B Preparation method of amino-substituted benzopyridine nitrogen-containing heterocycle 北京六合宁远科技有限公司 2021-08-24 CN claimed
CN-113072585-A Preparation of chiral aryl phosphonic acid cyclic diester and derivative thereof 厦门市博瑞来医药科技有限公司 2021-07-06 CN claimed
EP-4623914-A1 USE OF 8-HYDROXYQUINOLINE DERIVATIVE Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-10-01 EP disclosed
CN-120035438-A Use of 8-hydroxyquinoline derivatives 江苏亚虹医药科技股份有限公司 2025-05-23 CN disclosed
US-20240246916-A1 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2024-07-25 US disclosed
WO-2024109684-A1 USE OF 8-HYDROXYQUINOLINE DERIVATIVE 江苏亚虹医药科技股份有限公司 2024-05-30 WO disclosed
US-11993614-B2 Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2024-05-28 US disclosed
CN-118059101-A Use of 8-hydroxyquinoline derivatives 江苏亚虹医药科技股份有限公司 2024-05-24 CN disclosed
CN-117865886-B N- (quinoline-8-yl) quinoline-8-sulfonamide compound and application thereof 中国药科大学 2024-05-10 CN disclosed
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 US disclosed
EP-1663980-A1 QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLAXO GROUP LIMITED (GB) 2006-06-07 EP disclosed
US-20050124628-A1 Novel compounds ROIVANT NEUROSCIENCES LTD. (BM) 2005-06-09 US disclosed
WO-2005026125-A1 QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLAXO GROUP LIMITED (GB) 2005-03-24 WO disclosed
EP-1497266-A2 QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS GLAXO GROUP LIMITED (GB) 2005-01-19 EP disclosed
EP-0876345-B1 HETEROCYCLIC COMPOUNDS AS H+-ATPASES FUJISAWA PHARMACEUTICAL CO (JP) 2004-08-18 EP disclosed
WO-2003080580-A2 QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS GLAXO GROUP LIMITED (GB) 2003-10-02 WO disclosed
US-6008230-A TREATING BONE DISEASES CAUSED BY ABNORMAL BONE METABOLISM IN HUMAN BEING OR ANIMALS AS THE INHIBITORS OF BONE RESORPTION OR THE INHIBITORS OF BONE METASTASIS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-12-28 US disclosed
EP-0876345-A1 HETEROCYCLIC COMPOUNDS AS H+-ATPASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-11-11 EP disclosed
WO-1997014681-A1 HETEROCYCLIC COMPOUNDS AS H+-ATPASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124628-A1 Novel compounds NLN, ATP6V1B2, CHRNA2 KMT2A 2441/4885HTT 253/4885DYRK1A 3064/4885
US-20240246916-A1 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF CYP3A7, UGT1A7, UGT2B7 KMT2A 2738/4885HTT 2287/4885DYRK1A 4501/4885
US-11993614-B2 Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors PRMT5, PRMT1, PRMT8 KMT2A 87/4885HTT 3924/4885DYRK1A 2134/4885
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 KMT2A 1323/4885HTT 708/4885DYRK1A 2163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.